247 related articles for article (PubMed ID: 23573240)
1. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
[TBL] [Abstract][Full Text] [Related]
2. Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Zarrin P; Dehghani Ashkezari M; Seifati SM
J Mol Neurosci; 2021 Dec; 71(12):2583-2592. PubMed ID: 34125397
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
4. Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.
Ryu J; Zhang R; Hong BH; Yang EJ; Kang KA; Choi M; Kim KC; Noh SJ; Kim HS; Lee NH; Hyun JW; Kim HS
PLoS One; 2013; 8(8):e71178. PubMed ID: 23976995
[TBL] [Abstract][Full Text] [Related]
5. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Chagniel L; Robitaille C; Lebel M; Cyr M
Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson's disease: motor and non-motor outcomes.
Bigham M; Mohammadipour A; Hosseini M; Malvandi AM; Ebrahimzadeh-Bideskan A
Metab Brain Dis; 2021 Jun; 36(5):927-937. PubMed ID: 33656625
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
Hu LF; Lu M; Tiong CX; Dawe GS; Hu G; Bian JS
Aging Cell; 2010 Apr; 9(2):135-46. PubMed ID: 20041858
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of plastrum testudinis extract on dopaminergic neurons in a Parkinson's disease model through DNMT1 nuclear translocation and SNCA's methylation.
Ye S; Zhong J; Huang J; Chen L; Yi L; Li X; Lv J; Miao J; Li H; Chen D; Li C
Biomed Pharmacother; 2021 Sep; 141():111832. PubMed ID: 34153844
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
El Nebrisi E; Javed H; Ojha SK; Oz M; Shehab S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023066
[TBL] [Abstract][Full Text] [Related]
11. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
12. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
15. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease.
Du XX; Xu HM; Jiang H; Song N; Wang J; Xie JX
Neurosci Bull; 2012 Jun; 28(3):253-8. PubMed ID: 22622825
[TBL] [Abstract][Full Text] [Related]
16. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
17. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Jalali MS; Saki G; Farbood Y; Azandeh SS; Mansouri E; Ghasemi Dehcheshmeh M; Sarkaki A
J Chem Neuroanat; 2021 Apr; 113():101921. PubMed ID: 33600923
[TBL] [Abstract][Full Text] [Related]
19. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
[TBL] [Abstract][Full Text] [Related]
20. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
